{"id":3373,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"1992-01-22","marketCap":82848.6,"name":"Gilead Sciences Inc","phone":"16505743000","outstanding":1246.97,"symbol":"GILD","website":"https://www.gilead.com/","industry":"Biotechnology"},"price":66.427475,"year":2024,"month":4,"day":26,"weekday":"Friday","title":"Historical Stock Splits and Corporate Actions: Gilead Sciences Inc","date":"2024-04-26","url":"/posts/2024/04/26/GILD","content":[{"section":"1988 - 1991: Gilead Sciences Inc Founding and IPO","text":"1988: Gilead Sciences Inc is founded by Michael L. Riordan, a medical doctor.\n\n1992: The company goes public with an initial public offering (IPO)."},{"section":"1997 - 2001: Stock Split and Acquisitions","text":"1997: Gilead Sciences executes a 2-for-1 stock split.\n\n1999: Gilead Sciences acquires NeXstar Pharmaceuticals, expanding its portfolio.\n\n2001: The company acquires Triangle Pharmaceuticals, further bolstering its drug development capabilities."},{"section":"2004 - 2007: Major Acquisition and Stock Split","text":"2004: Gilead Sciences makes a significant acquisition by purchasing Corus Pharma, enhancing its respiratory product pipeline.\n\n2006: A 2-for-1 stock split occurs, increasing the number of outstanding shares.\n\n2007: Gilead Sciences acquires Myogen Inc, gaining access to cardiovascular therapies."},{"section":"2011 - 2014: Dividends and Acquisitions","text":"2011: Gilead Sciences begins paying dividends to shareholders.\n\n2011: The company acquires Pharmasset, obtaining breakthrough hepatitis C drug candidates.\n\n2012: A major 2-for-1 stock split takes place.\n\n2014: Gilead Sciences acquires Kite Pharma, venturing into the field of cell therapy."},{"section":"2015 - Present: CoVid-19 Pandemic and Recent Events","text":"2015: Gilead Sciences introduces its hepatitis C drug, Sovaldi, revolutionizing treatment.\n\n2016: A 2-for-1 stock split occurs.\n\n2020: Gilead Sciences' antiviral drug, Remdesivir, gains attention as a potential treatment for COVID-19.\n\n2020: Gilead Sciences initiates various clinical trials and research efforts related to COVID-19 treatments.\n\n2021: The company announces a $21 billion acquisition of Immunomedics, expanding its oncology portfolio."}],"tags":["OverSold","Long","Biotechnology"],"news":[{"category":"company","date":1714133463,"headline":"Q1 2024 Gilead Sciences Inc Earnings Call","id":127244230,"image":"","symbol":"GILD","publisher":"Yahoo","summary":"Q1 2024 Gilead Sciences Inc Earnings Call","url":"https://finance.yahoo.com/news/q1-2024-gilead-sciences-inc-121103209.html"},{"category":"company","date":1714132800,"headline":"FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV","id":127244231,"image":"https://s.yimg.com/ny/api/res/1.2/QzTNW33.tVGNKqRmX76ztg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00MDA-/https://media.zenfs.com/en/business-wire.com/701a162d3e721bc78a02e966b681d24f","symbol":"GILD","publisher":"Yahoo","summary":"FOSTER CITY, Calif., April 26, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads. These additional data stem from Study 5310, which evaluated the pharmacokinetics, safety and efficacy of","url":"https://finance.yahoo.com/news/fda-approves-biktarvy-label-data-120000380.html"},{"category":"company","date":1714116900,"headline":"Gilead Sciences Inc (GILD) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ...","id":127244232,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"GILD","publisher":"Yahoo","summary":"Explore Gilead's latest financial performance and strategic directions, including updates on HIV, oncology, and liver disease segments.","url":"https://finance.yahoo.com/news/gilead-sciences-inc-gild-q1-073500074.html"},{"category":"company","date":1714095915,"headline":"Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript","id":127236507,"image":"https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg","symbol":"GILD","publisher":"Yahoo","summary":"GILD earnings call for the period ending March 31, 2024.","url":"https://www.fool.com/earnings/call-transcripts/2024/04/25/gilead-sciences-gild-q1-2024-earnings-call-transcr/?source=eptyholnk0000202\u0026amp;utm_source=yahoo-host-full\u0026amp;utm_medium=feed\u0026amp;utm_campaign=article\u0026amp;.tsrc=rss"},{"category":"company","date":1714082408,"headline":"Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say","id":127236508,"image":"https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba","symbol":"GILD","publisher":"Yahoo","summary":"Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.","url":"https://finance.yahoo.com/news/gilead-gild-reports-q1-earnings-220008000.html"},{"category":"company","date":1714081740,"headline":"Gilead Beats Earnings Expectations After Rocky Quarter","id":127236509,"image":"","symbol":"GILD","publisher":"Yahoo","summary":"The biotech reported a loss for the quarter of $1.32 per share, better than the FactSet consensus estimate of a loss of $1.49 per share.","url":"https://finance.yahoo.com/m/219ac92c-47c2-3ee8-8a83-f7bb3539b573/gilead-beats-earnings.html"},{"category":"company","date":1714081311,"headline":"Gilead Sciences Inc (GILD) Q1 2024 Earnings: Misses Analyst EPS Estimates Amid Significant ...","id":127236510,"image":"","symbol":"GILD","publisher":"Yahoo","summary":"Comprehensive Analysis of Gilead's First Quarter Financial Performance","url":"https://finance.yahoo.com/news/gilead-sciences-inc-gild-q1-214151392.html"},{"category":"company","date":1714079703,"headline":"Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates","id":127236511,"image":"https://media.zenfs.com/en/zacks.com/090f58c1efbe3555b861102525e50b39","symbol":"GILD","publisher":"Yahoo","summary":"Gilead (GILD) delivered earnings and revenue surprises of 11.41% and 5.59%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?","url":"https://finance.yahoo.com/news/gilead-sciences-gild-reports-q1-211503328.html"},{"category":"company","date":1714077647,"headline":"Gilead Notches A Quarterly Beat On The Back Of Its Covid Drug, Again","id":127236512,"image":"https://media.zenfs.com/en/ibd.com/7ce26b4b87cc5cc7683c1900afb4c75b","symbol":"GILD","publisher":"Yahoo","summary":"Gilead beat first-quarter calls, but it came on the back of Covid drug Veklury. And Gilead stock jumped in late trades Thursday.","url":"https://finance.yahoo.com/m/a7f6d37a-39c1-39c8-9f9a-e22c82514dfd/gilead-notches-a-quarterly.html"},{"category":"company","date":1714076765,"headline":"Gilead Sciences, Inc. (GILD) Q1 2024 Earnings Call Transcript","id":127229115,"image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","symbol":"GILD","publisher":"SeekingAlpha","summary":"Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Q1 2024 Earnings Conference Call April 25, 2024 4:30 PM ETCompany ParticipantsJacquie Ross - Vice President,...","url":"https://seekingalpha.com/article/4686465-gilead-sciences-inc-gild-q1-2024-earnings-call-transcript"},{"category":"company","date":1714076074,"headline":"Gilead Sciences, Inc. 2024 Q1 - Results - Earnings Call Presentation","id":127228817,"image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","symbol":"GILD","publisher":"SeekingAlpha","summary":"The following slide deck was published by Gilead Sciences, Inc.","url":"https://seekingalpha.com/article/4686461-gilead-sciences-inc-2024-q1-results-earnings-call-presentation"},{"category":"company","date":1714075896,"headline":"Gilead posts quarterly loss, revenue rises 5%","id":127221676,"image":"https://media.zenfs.com/en/reuters-finance.com/de6fddb5dde53d7945a8f1ba1f40c5c6","symbol":"GILD","publisher":"Yahoo","summary":"Gilead Sciences reported a first-quarter loss on Thursday after taking a $3.9 billion charge for its recent acquisition of liver drug developer CymaBay Therapeutics, while revenue rose 5% on higher HIV, oncology and liver disease treatment sales.  For full-year 2024, Gilead said it still expects product sales of $27.1 billion to $27.5 billion, but lowered its earnings outlook to include the recent charge as well as incremental expenses related to the CymaBay deal.  Wall Street analysts currently project Gilead's 2024 earnings at $3.94 a share on revenue of $27.5 billion, according to LSEG data.","url":"https://finance.yahoo.com/news/gilead-posts-quarterly-loss-revenue-201136712.html"},{"category":"company","date":1714075667,"headline":"Will Gilead's Big Veklury Beat Offset A Cancer Drug Miss?","id":127221677,"image":"https://media.zenfs.com/en/ibd.com/7ce26b4b87cc5cc7683c1900afb4c75b","symbol":"GILD","publisher":"Yahoo","summary":"Gilead beat first-quarter calls, but it came on the back of Covid drug Veklury. And Gilead stock could take hit Thursday.","url":"https://finance.yahoo.com/m/a7f6d37a-39c1-39c8-9f9a-e22c82514dfd/will-gilead%27s-big-veklury.html"},{"category":"company","date":1714075320,"headline":"Gilead Sciences Announces First Quarter 2024 Financial Results","id":127236513,"image":"https://s.yimg.com/ny/api/res/1.2/QzvA2mAO.cOV0jt1HNKDVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00MDA-/https://media.zenfs.com/en/business-wire.com/80c16dd2d9946946e8ecdf2ecc03f9b7","symbol":"GILD","publisher":"Yahoo","summary":"FOSTER CITY, Calif., April 25, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations.","url":"https://finance.yahoo.com/news/gilead-sciences-announces-first-quarter-200200212.html"},{"category":"company","date":1714067356,"headline":"These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)","id":127224862,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1482998631/image_1482998631.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"The Annual Meeting of ASCO is a major event for clinicians and researchers in the field of oncology. Explore more details here.","url":"https://seekingalpha.com/article/4686392-these-are-the-biotechs-showing-up-at-the-biggest-cancer-meeting-of-the-year-oral-presentations"},{"category":"company","date":1714063225,"headline":"Gilead Sciences Posts Higher 1Q Sales, Swings to Loss on Charges","id":127222465,"image":"","symbol":"GILD","publisher":"Finnhub","summary":"By Paul Ziobro Gilead Sciences posted higher first-quarter sales, but swung to a steep loss due to charges related to recent acquisitions, prompting the company to cut its per-share profit...","url":"https://finnhub.io/api/news?id=f865e37d2899cba02ae2686220b306f9b1bb6c7b061de8ff24b2a9cf7ca8b84b"},{"category":"company","date":1714061719,"headline":"Gilead: Q1 Earnings Snapshot","id":127221661,"image":"","symbol":"GILD","publisher":"Finnhub","summary":"FOSTER CITY, Calif. — FOSTER CITY, Calif. — Gilead Sciences Inc. on Thursday reported a loss of $4.17 billion in its first quarter. The Foster City, California-based company said it had a...","url":"https://finnhub.io/api/news?id=2c782baf03729c4ef97c9446ed58f55a736a69c1e3884d716db115a02b2db09f"},{"category":"company","date":1714048680,"headline":"Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?","id":127217773,"image":"","symbol":"GILD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3461617283"},{"category":"company","date":1714046940,"headline":"Notable companies reporting after market close","id":127217774,"image":"","symbol":"GILD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3461565985"},{"category":"company","date":1714032600,"headline":"March's Dividend Portfolio Update Sets New All-Time Record - 100 Holdings, 21 Buys","id":127210189,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1503371245/image_1503371245.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Portfolio changes in March focus on BDCs, aiming to increase dividend income by at least $100 each month. Click here for a detailed analysis.","url":"https://seekingalpha.com/article/4685904-marchs-dividend-portfolio-update-sets-new-all-time-record-100-holdings-21-buys"},{"category":"company","date":1714032000,"headline":"Polaris Global Equity Composite Q1 2024 Commentary","id":127210034,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1303046106/image_1303046106.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Global equity markets enjoyed consecutive months of gains, with the MSCI World Index returning 9.01% for the quarter.","url":"https://seekingalpha.com/article/4686064-polaris-global-equity-composite-q1-2024-commentary"},{"category":"company","date":1714029660,"headline":"Analysts Offer Insights on Healthcare Companies: Amedisys (AMED) and Gilead Sciences (GILD)","id":127226767,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3461103653"},{"category":"company","date":1714025160,"headline":"Options Volatility and Implied Earnings Moves Today, April 25, 2024","id":127215905,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3461010840"},{"category":"company","date":1714024800,"headline":"Gilead has strong Q1, but updated 2024 EPS guidance range misses consensus","id":127226773,"image":"","symbol":"GILD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3462231561"},{"category":"company","date":1714022580,"headline":"US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst","id":127214601,"image":"","symbol":"GILD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3460967585"},{"category":"company","date":1714018920,"headline":"Fly Intel: After-Hours Movers","id":127224374,"image":"","symbol":"GILD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3462032123"},{"category":"company","date":1714015620,"headline":"Gilead Sciences in charts: Revenue from oncology rises most among products; Veklury dips in Q1","id":127226778,"image":"","symbol":"GILD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3461918546"},{"category":"company","date":1714014540,"headline":"Gilead Sciences Non-GAAP EPS of -$1.32 beats by $0.20, revenue of $6.69B beats by $350M","id":127226779,"image":"","symbol":"GILD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3461885074"},{"category":"company","date":1714014240,"headline":"Gilead cuts FY24 adjusted EPS view to $3.45-$3.85 from $6.85-$7.25","id":127226780,"image":"","symbol":"GILD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3461878029"},{"category":"company","date":1714014180,"headline":"Gilead reports Q1 adjusted EPS ($1.32), consensus ($1.39)","id":127226781,"image":"","symbol":"GILD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3461876422"},{"category":"company","date":1714011540,"headline":"Gilead options imply 3.2% move in share price post-earnings","id":127226782,"image":"","symbol":"GILD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3461797333"},{"category":"company","date":1713983312,"headline":"Inflation Reduction Act: A Bullish Catalyst For Viatris Inc.","id":127194571,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1635084121/image_1635084121.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Discover the impact of the Inflation Reduction Act on generic drugs, benefiting certain stocks in the pharmaceutical sector. Click here to read an analysis on VTRS stock now.","url":"https://seekingalpha.com/article/4685874-inflation-reduction-act-a-bullish-catalyst-for-viatris"},{"category":"company","date":1713964740,"headline":"What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?","id":127184290,"image":"https://media.zenfs.com/en/zacks.com/12dfb060a52eb196f98ee11cc492ea9d","symbol":"GILD","publisher":"Yahoo","summary":"Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.","url":"https://finance.yahoo.com/news/whats-store-5-pharma-bigwigs-131900428.html"},{"category":"company","date":1713963750,"headline":"Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage","id":127185874,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1483000268/image_1483000268.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Madrigal recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH. Check out my analysis of MDGL stock here.","url":"https://seekingalpha.com/article/4685718-madrigal-2-challenges-to-overcome-to-maintain-nash-first-mover-advantage"},{"category":"company","date":1713961620,"headline":"HSBC gets more bullish on Gilead, upgrades shares","id":127195874,"image":"","symbol":"GILD","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3459494309"},{"category":"company","date":1713921120,"headline":"Gilead Sciences Q1 Preview: HIV pipeline, FY24 guidance in focus","id":127195877,"image":"","symbol":"GILD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3459566589"},{"category":"company","date":1713880863,"headline":"Incyte (INCY) Earnings Expected to Grow: Should You Buy?","id":127161901,"image":"https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248","symbol":"GILD","publisher":"Yahoo","summary":"Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.","url":"https://finance.yahoo.com/news/incyte-incy-earnings-expected-grow-140103175.html"},{"category":"company","date":1713877968,"headline":"3 Potential Biopharma Buyout Targets","id":127161456,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1479134763/image_1479134763.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Drug blockbusters facing key patent expirations and Big Pharma's surplus of cash suggest increased M\u0026A volume in the coming year. Click here to read our picks.","url":"https://seekingalpha.com/article/4685355-3-potential-biopharma-buyout-targets"},{"category":"company","date":1713862803,"headline":"Gilead Q1 Earnings Preview: Most Gains Wiped Out - Cause For Concern?","id":127157381,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1319956561/image_1319956561.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Gilead Sciences will report its Q1 2024 earnings on Thursday, April 25. Check out whether GILD stock is a good buy ahead of Q1 earnings.","url":"https://seekingalpha.com/article/4685264-gilead-q1-earnings-preview-most-gains-wiped-out-cause-for-concern"},{"category":"company","date":1713808620,"headline":"Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?","id":127151902,"image":"https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619","symbol":"GILD","publisher":"Yahoo","summary":"Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.","url":"https://finance.yahoo.com/news/gilead-gild-gears-report-q1-175700025.html"},{"category":"company","date":1713798248,"headline":"Mirum Pharmaceuticals: After Phase 2 Miss, An iBAT Inhibitor On Deck To Drive Value","id":127141693,"image":"https://media.gettyimages.com/id/2149039460/photo/experiment-microscope-and-sample-with-woman-scientist-in-laboratory-for-breakthrough-or.jpg?b=1\u0026s=170667a\u0026w=0\u0026k=20\u0026c=CzEScWG8q2mRtxzFeirj6FClEnd5-mHw4SxazGvMY8E=","symbol":"GILD","publisher":"SeekingAlpha","summary":"FDA approved Mirum Pharmaceuticals' Limvarli for treatment of cholestatic pruritus in patients with PFIC. Learn why I rate MIRM stock a buy.","url":"https://seekingalpha.com/article/4685141-mirum-pharmaceuticals-mirm-phase-2-miss-ibat-inhibitor-drive-value"},{"category":"company","date":1713795623,"headline":"Hookipa Pharma: 04/25/24 Update Should Be The First Of Several Positive Catalysts","id":127140770,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1350525671/image_1350525671.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Hookipa Pharma's positive data could push shares up 3-5x while negative news could cut the stock in half or worse. Check out more on HOOK stock here.","url":"https://seekingalpha.com/article/4685130-hookipa-pharma-042524-update-should-be-the-first-of-several-positive-catalysts"},{"category":"company","date":1713791765,"headline":"Insights Into Gilead (GILD) Q1: Wall Street Projections for Key Metrics","id":127142064,"image":"https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85","symbol":"GILD","publisher":"Yahoo","summary":"Besides Wall Street's top -and-bottom-line estimates for Gilead (GILD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.","url":"https://finance.yahoo.com/news/insights-gilead-gild-q1-wall-131605255.html"},{"category":"company","date":1713791083,"headline":"Be Greedy When Others Are Fearful, Even If They Are Fearful For A Good Reason","id":127139082,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1398379170/image_1398379170.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Investors caught off guard by increased geopolitical risk may face short-term selling pressure, potentially worsening the S\u0026P 500's drawdown. Read here for details.","url":"https://seekingalpha.com/article/4685108-be-greedy-when-others-are-fearful-even-if-they-are-fearful-for-a-good-reason"},{"category":"company","date":1713787380,"headline":"Gilead Sciences: Some Signs Of An Impending Bottom","id":127137976,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1129163219/image_1129163219.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Gilead Sciencesâ stock underperformed market substantially over past decade. It offers a high 4.61% dividend yield. Read my earnings analysis of GILD stock here.","url":"https://seekingalpha.com/article/4685090-gilead-sciences-some-signs-of-an-impending-bottom"},{"category":"company","date":1713748920,"headline":"Undervalued Icons: 3 Household Names Trading at Steep Discounts","id":127143914,"image":"","symbol":"GILD","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3455893329"},{"category":"company","date":1713683100,"headline":"Earnings week ahead: Tesla, Meta Platforms, Google, Microsoft, Intel, Exxon Mobil, and more","id":127128647,"image":"","symbol":"GILD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3454493428"},{"category":"company","date":1713614580,"headline":"THQ: Collecting A High Yield From Increased Medical Spending","id":127119950,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1868353991/image_1868353991.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"abrdn Healthcare Opportunities Fund (THQ) offers a high dividend yield and exposure to diverse healthcare subsectors, outperforming peers. Explore more here.","url":"https://seekingalpha.com/article/4684905-thq-collecting-a-high-yield-from-increased-medical-spending-cef"},{"category":"company","date":1713563419,"headline":"Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know","id":127111033,"image":"https://media.zenfs.com/en/zacks.com/d7dcbe11345e3f8e5e71e6827fe3c4c9","symbol":"GILD","publisher":"Yahoo","summary":"Gilead Sciences (GILD) closed the most recent trading day at $66.76, moving +0.91% from the previous trading session.","url":"https://finance.yahoo.com/news/gilead-sciences-gild-increases-despite-215019834.html"},{"category":"company","date":1713520380,"headline":"Interesting GILD Put And Call Options For July 19th","id":127112042,"image":"","symbol":"GILD","publisher":"Stock Options Channel","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3452065036"},{"category":"company","date":1713515400,"headline":"FDA Mandates \"Boxed Warning\" For Bristol Myers, Johnson \u0026 Johnson CAR-T-Based Blood Cancer Therapies","id":127100829,"image":"","symbol":"GILD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3451967663"},{"category":"company","date":1713509460,"headline":"Analysts Are Bullish on These Healthcare Stocks: Gilead Sciences (GILD), Biogen (BIIB)","id":127100366,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3451856524"},{"category":"company","date":1713503640,"headline":"FDA requires labeling changes to CAR-T cell therapies to reflect cancer risk","id":127100830,"image":"","symbol":"GILD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3451763528"},{"category":"company","date":1713499980,"headline":"Hepion ends Phase 2 study for NASH drug due to cash restraints","id":127108932,"image":"","symbol":"GILD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3452566589"},{"category":"company","date":1713479589,"headline":"US FDA mandates label updates on CAR-T cancer therapies","id":127094045,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"GILD","publisher":"Yahoo","summary":"The U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology will require changes to the so-called \"boxed warning\" to highlight the serious risk of T-cell blood cancer in patients who use these therapies.  The health regulor has required related updates to other sections of the label such as warnings and precautions, postmarketing experience, patient counseling information and medication guide.  In January, the FDA asked a host of drugmakers including Gilead Sciences, Johnson \u0026 Johnson and Novartis to add a boxed warning to their CAR-T cancer therapies, as it received reports of patients developing a type of T-cell blood cancer after being treated with them.","url":"https://finance.yahoo.com/news/us-fda-mandates-label-updates-223309187.html"},{"category":"company","date":1713477620,"headline":"Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know","id":127100063,"image":"https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1","symbol":"GILD","publisher":"Yahoo","summary":"Gilead Sciences (GILD) closed at $66.16 in the latest trading session, marking a -1.15% move from the prior day.","url":"https://finance.yahoo.com/news/gilead-sciences-gild-sees-more-220020430.html"},{"category":"company","date":1713462300,"headline":"Gilead Sciences Publishes 2023 ESG Impact Report","id":127084520,"image":"https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613","symbol":"GILD","publisher":"Yahoo","summary":"NORTHAMPTON, MA / ACCESSWIRE / April 18, 2024 / Gilead Sciences published its 2023 Environmental, Social and Governance (ESG) Impact Report, which uses the ESG framework to highlight the successes and achievements of the prior year. In this year's ...","url":"https://finance.yahoo.com/news/gilead-sciences-publishes-2023-esg-174500646.html"},{"category":"company","date":1713448899,"headline":"Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for","id":127081284,"image":"https://media.zenfs.com/en/zacks.com/432476d296d64c50172213c0415587c9","symbol":"GILD","publisher":"Yahoo","summary":"Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.","url":"https://finance.yahoo.com/news/analysts-estimate-gilead-sciences-gild-140139125.html"},{"category":"company","date":1713448769,"headline":"Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value","id":127081093,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/168166178/image_168166178.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Caribou Biosciences, Inc. expects promising phase 1 studies on CB-010 and CB-011 for various lymphoma and myeloma treatments by Q2 2024. Click for my CRBU update.","url":"https://seekingalpha.com/article/4684523-caribou-biosciences-two-clinical-data-updates-in-2024-could-bring-value"},{"category":"company","date":1713446778,"headline":"ALX Oncology: Trying To Justify The Hype","id":127080348,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/81860632/image_81860632.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"ALX Oncology'sÂ has a strong financial position withÂ evorpacept, which has shown encouraging results for various cancer therapies. See more on ALXO stock here.","url":"https://seekingalpha.com/article/4684509-alx-oncology-trying-to-justify-the-hype"},{"category":"company","date":1713442800,"headline":"What the Options Market Tells Us About Gilead Sciences","id":127090882,"image":"","symbol":"GILD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3450500544"},{"category":"company","date":1713433380,"headline":"Stifel starts Mirum at buy, cites IBATi drug potential","id":127088851,"image":"","symbol":"GILD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3450285749"},{"category":"company","date":1713416820,"headline":"Hold Rating on Gilead Sciences Amidst Q1 Revenue Shortfall and Acquisition Concerns","id":127083829,"image":"","symbol":"GILD","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3449974241"},{"category":"company","date":1713337200,"headline":"ClearBridge Sustainability Leaders Strategy Q1 2024 Portfolio Manager Commentary","id":127051576,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1340690117/image_1340690117.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"U.S. equities continued their upward march in the first quarter as the momentum rally, begun following Novemberâs inflation print, showed few signs of flagging.","url":"https://seekingalpha.com/article/4684199-clearbridge-sustainability-leaders-strategy-q1-2024-portfolio-manager-commentary"},{"category":"company","date":1713333780,"headline":"GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO INNOVATIVE INITIATIVES IN ASIA","id":127052585,"image":"https://media.zenfs.com/en/prnewswire.com/18ef42744c262c27f9ba2cdb133c621b","symbol":"GILD","publisher":"Yahoo","summary":"Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant (\"Grant\") to support community-backed innovative projects associated with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV). An official announcement was made at a Gilead-hosted symposium titled \"Partnering for Global Health Equity: Case Studies from Around the World,\" held during the World Hepatitis Summit (\"Summit\") in Lisbon.","url":"https://finance.yahoo.com/news/gilead-sciences-join-forces-world-060300915.html"},{"category":"company","date":1713325680,"headline":"Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors","id":127090886,"image":"","symbol":"GILD","publisher":"MarketWatch","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3448998553"},{"category":"company","date":1713317700,"headline":"If You Invested $100 In This Stock 20 Years Ago, You Would Have $900 Today","id":127059851,"image":"","symbol":"GILD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3448805041"},{"category":"company","date":1713273240,"headline":"Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why","id":127031058,"image":"https://media.zenfs.com/en/zacks.com/6ee3794b7c66423fbb5bd782d2c16aad","symbol":"GILD","publisher":"Yahoo","summary":"Xilio (XLO) rallies 79.8% in a month on an exclusive global licensing agreement with Gilead Sciences to develop XTX301 for advanced solid tumors.","url":"https://finance.yahoo.com/news/xilios-xlo-shares-surge-79-131400846.html"},{"category":"company","date":1713272410,"headline":"Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know","id":127032844,"image":"https://media.zenfs.com/en/zacks.com/3cb5117fc22f5e37890d1860dcd61f9f","symbol":"GILD","publisher":"Yahoo","summary":"Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.","url":"https://finance.yahoo.com/news/gilead-sciences-inc-gild-attracting-130010099.html"},{"category":"company","date":1713258950,"headline":"Pfizer's Doldrums, Just A Bad Case Of COVID-19?","id":127030002,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1351419442/image_1351419442.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Pfizer may be worth buying as the COVID-based product revenues decline and equilibrate. Click here to read why I'm bullish on PFE stock.","url":"https://seekingalpha.com/article/4683994-pfizer-doldrums-just-a-bad-case-of-covid-19-pfe-stock"},{"category":"company","date":1713182400,"headline":"Should You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq?","id":127011027,"image":"https://g.foolcdn.com/editorial/images/772686/man-holding-cash-dividends.jpg","symbol":"GILD","publisher":"Yahoo","summary":"Dividend stocks can be a smart way to ride out market volatility.","url":"https://www.fool.com/investing/2024/04/15/should-you-buy-the-3-highest-paying-dividend-stock/?source=eptyholnk0000202\u0026amp;utm_source=yahoo-host-full\u0026amp;utm_medium=feed\u0026amp;utm_campaign=article\u0026amp;.tsrc=rss"},{"category":"company","date":1713157560,"headline":"GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY-LED INITIATIVES IN ASIA","id":127010171,"image":"https://media.zenfs.com/en/prnewswire.com/18ef42744c262c27f9ba2cdb133c621b","symbol":"GILD","publisher":"Yahoo","summary":"Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant (\"Grant\") to support community-backed innovative projects associated with hepatitis B (HBV), hepatitis C (HCV), and hepatitis D (HDV) in conjunction with the World Hepatitis Summit (\"Summit\"). An official announcement was made at a Gilead-hosted symposium titled \"Partnering for Global Health Equity: Case Studies from Around the World,\" held during the World Hepatitis Summit (\"Summit\"","url":"https://finance.yahoo.com/news/gilead-sciences-join-forces-world-050600305.html"},{"category":"company","date":1713154920,"headline":"GILEAD SCIENCES JOIN FORCES WITH WORLD HEPATITIS ALLIANCE AND EXPERTS TO AWARD US$4 MILLION ALL4LIVER GRANT FOR VIRAL HEPATITIS ELIMINATION BY 2030, INCLUDING TWO COMMUNITY LED INITIATIVES IN HONG KONG","id":127008266,"image":"https://media.zenfs.com/en/prnewswire.com/18ef42744c262c27f9ba2cdb133c621b","symbol":"GILD","publisher":"Yahoo","summary":"Gilead Sciences, Inc. (Nasdaq: GILD), announced a global distribution of US$4 million through its ALL4LIVER Grant (\"Grant\") to support community-backed innovative projects associated with hepatitis C, hepatitis B, and hepatitis D in conjunction with the World Hepatitis Summit (\"Summit\"). An official announcement was made at a Gilead-hosted symposium titled \"Partnering for Global Health Equity: Case Studies from Around the World,\" held during the World Hepatitis Summit (\"Summit\") in Lisbon from 9","url":"https://finance.yahoo.com/news/gilead-sciences-join-forces-world-042200925.html"},{"category":"company","date":1712959219,"headline":"Gilead Sciences (GILD) Stock Moves -0.84%: What You Should Know","id":126990531,"image":"https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b","symbol":"GILD","publisher":"Yahoo","summary":"In the most recent trading session, Gilead Sciences (GILD) closed at $68.07, indicating a -0.84% shift from the previous trading day.","url":"https://finance.yahoo.com/news/gilead-sciences-gild-stock-moves-220019609.html"},{"category":"company","date":1712915280,"headline":"Stocks with the highest swings in option premium price over 3 months - JPM","id":126979403,"image":"","symbol":"GILD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3441550054"},{"category":"company","date":1712898708,"headline":"U.S. Wide-Moat Stocks On Sale - The April 2024 Heat Map","id":126975802,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/912585074/image_912585074.jpg?io=getty-c-w1536","symbol":"GILD","publisher":"SeekingAlpha","summary":"Our 3-step process focuses on wide-moat stocks (as per Morningstarâs rating). Read more to see the April 2024 heat map.","url":"https://seekingalpha.com/article/4683411-us-wide-moat-stocks-on-sale-the-april-2024-heat-map"}]}